News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference [Yahoo! Finance]

Alumis (ALMS) is now covered by Stifel Nicolaus. They set a "buy" rating and a $44.00 price target on the stock.

Alumis to Participate in Upcoming February Investor Conferences

Alumis (NASDAQ:ALMS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.

Form 5 ALUMIS INC. For: Dec 31 Filed by: Goldstein David M

Form S-8 ALUMIS INC.

Form 4 ALUMIS INC. For: Jan 26 Filed by: Pangali Sanam

Form 4 ALUMIS INC. For: Jan 26 Filed by: Babler Martin

Form 4 ALUMIS INC. For: Jan 26 Filed by: Hardiman Roy C.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}